Factor XI deficiency is a rare bleeding diathesis found predominantly in Ashkenazi Jewish kindreds. A recent study of six Jewish patients identified three distinct mutations (Types 1, 11, and 111) in the factor XI gene that were sufficient to fully define the genotypes of the patients. We have investigated 63 patients with factor XI deficiency and find overall allele frequencies of 44% for the type II mutation, 31% for the type 111 mutation, and 0% for the type I mutation. Therefore, 25% of the mutant factor XI alleles in our sample remain unde-ACTOR XI DEFICIENCY is a rare coagulopathy F found predominantly but not exclusively in Ashkenazi Jewish kindreds where the defective allele occurs at a frequency of at least 4.3% .' It also occurs much less commonly in non-Jewish populations.' The disorder, first described by Rosenthal et al? is inherited as an autosomal incompletely recessive trait. Homozygous and heterozygous patients are identified by a severe or partial deficiency of factor XI, re~pectively,~ but both groups are at risk from increased bleeding. Unlike hemophilia A and B, the bleeding diathesis associated with factor XI deficiency is mild, typical symptoms including epistaxis, menorrhagia, bleeding after dental extraction, and prolonged postoperative or posttraumatic hemorrhage. However, rarer problems do include hemarthroses and muscle hematomas: This disorder is of particular interest because of the considerable variability in bleeding severity between individuals and the absence of any strong correlation with the plasma level of factor Some investigators have reported that the bleeding tendency is consistent within an individual kindred7,9 but other studies have found that the bleeding tendency within families is unpredictable? The lack of any obvious correlation between clinical phenotype and plasma factor XI level may be a reflection of different underlying defects of the factor XI protein. Alternatively, other genetic factors may play a role in determining the clinical phenotype of a factor XI-deficient patient. This disorder may, therefore, represent a paradigm for other coagulopathies, including the thrombotic states where coagulation assays do not fully predict clinical severity. fined. However, the distribution of mutant alleles is significantly different between Jewish and non-Jewish populations with hitherto undefined mutations accounting for 84% of the disease alleles in non-Jewish patients. Plasma factor XI:C levels were found to differ significantly between different homozygous and compound heterozygous genotypes and the inheritance of the 11/111 genotype was found to carry an increased risk of the most severe bleeding tendency.
Factor XI is a serine protease zymogen that links the contact phase of blood coagulation with the intrinsic pathway via the activation of factor IX. Factor XI, a 160-Kd glycoprotein, circulates as a homodimer that is cleaved by factor XIIa between Arg369 and Ile370 in each monomer to generate factor XIa. The activated protease thus comprises two N-terminal heavy chains and two C-terminal light chains that are held together by disulphide bonds. In vitro, the activation of factor XI requires high molecular weight kininogen (HMWK) and a negatively charged surface. Factor XIa remains bound to the surface through the binding of HMWK to a site (Phe56 --+ Ser86) in the factor XIa heavy chain.'" The sequence of a factor XI cDNA cloned from human liver" predicts that the protein is synthesized with an 18 amino acid N-terminal leader sequence. The catalytic triad of the protease active site is located in each of the two C-terminal light chains of the protein." The human factor XI gene spans 23 kb, comprises 15 exons,13 and is located on chromosome 4q35.I4
A recent study by Asakai et all5 identified three distinct factor XI gene mutations in six Ashkenazi Jewish patients homozygous for factor XI deficiency. A point mutation in the 5' splice donor site (GT -+ AT) of the last intron, found in one of 12 alleles, probably results in aberrant mRNA processing. A second point mutation, introducing a novel termination codon into exon 5 (Glu117 -+ Ter), accounted for 5 of 12 mutant alleles. Finally, a third point mutation in exon 9, resulting in the amino acid substitution Phe283 -+ Leu, was found in six of 12 alleles. This amino acid change occurs at a site that is conserved between factor XI and human plasma prekallikrein." These three mutations, called type I, 11, and 111, respectively, therefore fully defined the genotypes of the six patients examined." However, it should be noted that a causative role for the type I11 mutation has not yet been formally established by in vitro expression studies. While no correlation between genotype and clinical phenotype was found, the number of patients studied was too small for this observation to be conclusive.
We have investigated a large number of patients with factor XI deficiency, both Jewish and non-Jewish, to address three specific questions. First, do the previously described mutations account for all cases of factor XI deficiency? Second, is there any evidence of a correlation between genotype and clinical phenotype among a larger group of patients? Third, do the documented mutations described in Ashkenazi Jews also occur in non-Jewish 
MATERIALS AND METHODS

Patients
Patients attending the Royal Free Hospital, London, UK, formed the major group for this study. Factor XI levels and detailed clinical histories were available from a previous study of inheritance and bleeding in factor XI deficiency? Additional patients from Israel, Sweden, and other UK centers were also included; factor XI:C levels and clinical histories of these patients were provided by their attending physician.
Analysis of Mutant Alleles
High molecular weight genomic DNA was extracted from peripheral blood leukocytes. DNA (200 ng) was used in a polymerase chain reaction (PCR) of 40 cycles with 100 pmol of each oligonucleotide primer following the method of Saiki et a1. 16 The primers for the type I analysis were 5'-AGTGACCAACGAA-GAGTGCCA (5' end of exon 14) and 5'-TTGCATATATTCCAT-TGGCTAAGA (5' end of intron N), annealing at 55°C; the primers for the type I1 analysis were 5'-GAATCTGGAAGGTAC-TCATGTC (3' end of intron D) and 5'-ATCGACCACTCGAAT-GTCCTG (5' end of intron E), annealing at 60°C; the primers for the type 111 analysis were 5'-ACTTTACTTTCTCTAGGTGCTGT (3' end of intron G) and 5'-ACAGTCTTGATTGTGATGTAT-GAA (5' end of intron J), annealing at 60°C. Denaturation was performed at 94°C for 30 seconds, annealing at the specified temperature for 15 seconds and extension at 72°C for 5 minutes. After 40 cycles the reactions were held at 72°C for 10 minutes. PCR products were digested with Mae 111, Bsm I, and Sau3AI, respectively, and the digested products electrophoresed in 2.5% agarose gels containing ethidium bromide and visualised under UV light. Where appropriate (see Results), the validity of this restriction analysis was confirmed by direct sequencing of the PCR products" using one or both of the amplification oligonucleotides as sequencing primers in dideoxy chain termination reactions using modified T7 DNA polymerase (Sequenase; US Biochemical Corp, Cleveland, OH).
Statistical Analysis
Analysis of variance and F-tests were used to test the null hypothesis of equality of multiple (more than two) means, t-tests used to test for equality of two means, and X*-tests used to compare observed with predicted population frequencies. The analyses were performed according to established methods.18 Abbreviations used in reporting these tests are: SEM, standard error of the mean; DF, degrees of freedom.
RESULTS
Patient Pedigrees
Patients were designated homozygous or heterozygous deficient according to their plasma factor XI:C levels. 4 Of the 28 homozygous patients (0% to 20% FXI:C), 16 were unrelated sporadic cases and 12 were drawn from seven unrelated kindreds. The 35 heterozygotes (25% to 70% FXI:C) comprised six unrelated sporadic cases and 29 cases drawn from 11 unrelated kindreds. Thus, a total of 22 unrelated patients and 41 patients from 13 unrelated kindreds were included in the study. The pedigrees of each of these 13 kindreds are presented in the Appendix.
The clinical histories of 61 patients were assessed from available case notes by two physicians and the bleeding symptoms classified into one of three groups:
No bleeding despite hemostatic challenge as a result of surgery, dental extraction, or trauma; or, very occasional trivial bleeding episodes not requiring clinical intervention.
Mild. A clear history of episodes of excessive bleeding in response to hemostatic challenge not requiring specific treatment.
Recurrent bleeding in response to hemostatic challenges requiring specific treatment and/or blood transfusion; or one or more episodes of spontaneous hemorrhage. Table 1 shows that there is no significant difference in the factor XI:C level among homozygotes in each of these groups or between heterozygotes with mild or no bleeding. Therefore, these data are consistent with previous studieP in showing, first, that there is a poor correlation between plasma factor XI:C level and bleeding tendency and, second, that a substantial proportion of heterozygotes bleed excessively. In addition, it is apparent from the pedigrees given in the Appendix that the bleeding tendency within these families is variable.
Noneltrivial.
Moderate.
Molecular Genetic Analysis
All patients were tested for the presence of the three mutations described by Asakai et For detection of the type I mutation, exon 14 plus the 5' region of the following intron (intron N) was amplified by PCR and the 132-bp product digested with Mae 111. The G + A mutation at the intron boundary results in the loss of a Mae I11 restriction site. A wild-type PCR product is, therefore, cut into two fragments of 99 bp and 33 bp while a mutant product remains uncut (Fig 1) . To detect type I1 mutations, exon 5 was amplified by PCR, giving a product of 223 bp. The type I1 G --+ T mutation destroys a Bsm I site in the middle of exon 5. Thus, a wild-type product is cut into two fragments of 113 bp and 110 bp following Bsm I digestion, whereas a mutant product remains uncut (Fig 2) . To detect type I11 mutations, exons 8, 9, and 10 were amplified as a single PCR product of 706 bp and digested with Suu3AI. In the wild-type product, a single Suu3AI site in exon 10 gives two fragments of 578 bp and 128 bp, but the presence of the T + C mutation in exon 9 creates a new Suu3AI site resulting in three fragments of 328 bp, 251 bp, and 128 bp (Fig 3). Figures 1, 2 , and 3 illustrate these analyses, which follow a similar strategy to that devised by Asakai et al."
The restriction analysis was validated by direct sequencing of certain PCR products. For example, in every case where the restriction analysis failed to identify a known mutation, sequencing of all three PCR products from that patient was performed to confirm that one of the previously defined mutations had not been missed. In addition, a random 10% of PCR products that scored positive for type I1 or type 111 mutations on restriction analysis were also sequenced to confirm the presence of the predicted point mutations. In no case was any discrepancy found between the restriction and sequencing analyses. Table 2 shows that of the 91 mutant alleles expected in this group of patients, 37 had a type I1 mutation and 31 had a type 111 mutation. No example of a type I mutation was found. Therefore, 23 mutant factor XI alleles (25%) in our sample did not contain one of the previously described mutations. Among the non-Jewish patients, only two of the 19 expected mutant alleles contained a defined mutation, indicating that the majority of mutant factor XI alleles in this group were other than the three previously described. The PCR product obtained using the 5' (pcu) and 3' (pcd) primers described in Materials and Methods. The type 111, T + C point mutation is indicated and a Seu3Al restriction map given for a wild-type and mutant PCR product. (6) An agarose gel analysis of three patients. One patient has a wild-type pattern (lanes 1 and 2). one is homozygous forthe type 111 mutation (lanes 3 and 4) . and one is heterozygous for the type 111 mutation (lanes 5 and 6). In each case an undigested aliquot of the PCR reaction (even lanes) has been loaded alongside an aliquot digested with Sau3Al (odd lanes). The positions of 100-bp, 250-bp, and 600-bp markers are indicated alongside the gel. Summary of the factor XI gene mutations found in 28 homozygous and 35 heterozygous patients. The total number of expected mutations is therefore 91. Type I, II, and 111 mutations are those described previously by Asakai et all5 and are detailed in the text. Mutant alleles that were found not to contain any one of these three mutations are designated undefined (UND).
remainder, type I1 mutations were slightly more common than type 111 mutations. The analysis presented in Table 3 also shows that the distribution of mutations is significantly different between Jewish and non-Jewish populations (x' = 61.98; P < .001). In the latter, 84% alleles contained undefined mutations compared with 12% among Jewish patients.
Correlation of Genotype and Phenotype
We then investigated whether the measured plasma factor XI:C level correlated with factor XI genotype ( Table  4) . We found that the mean factor XI:C levels associated with the homozygous and compound heterozygous genotypes differed significantly (F = 4.69; P < .01). The statistical analysis was therefore taken further with those genotypes containing defined mutations (ie, II/III, 11/11, and III/III). The differences between mean plasma factor XI levels in this subset of genotypes were highly significant (F = 11.12; P < .005). The plasma factor XI:C levels associated with a II/II genotype were very low (range 0 U/dL to 1.5 U/dL, mean 0.62 U/dL), whereas those associated with the III/III genotype were the highest of this subset (range 3 To obtain an unbiased estimate of these allele frequencies, the genotypes of all unrelated sporadic cases and the index case of each family group were analyzed. In two kindreds (groups 6 and lo), a mutation not present in the index case was identified in another family member. These two alleles were also included in the analysis. Of the 62 cvaluablc allclcs analyzcd in this manner, 16 (25.9%) contained undefincd mutations (Table 3 ). Among the For personal use only. on October 30, 2017. by guest www.bloodjournal.org From U/dL to 20 U/dL, mean 11 U/dL). The II/III genotypeassociated factor XI:C levels were intermediate (range 0 U/dL to 6 U/dL, mean 2.87 U/dL) ( Table 4 ). There was no significant difference in plasma factor XI levels among the three heterozygote genotypes (Table 4) .
We next attempted to determine whether there was any correlation between the genotypes we had established for each patient and the clinical severity of their factor XI deficiency. Table 5 shows the distribution of clinical phenotypes for each homozygous and heterozygous genotype. It is clear that among heterozygotes no one particular mutation carries an increased likelihood of increased bleeding. However, the analysis presented in Table 5 does show that, among homozygous and compound heterozygous patients, 
DISCUSSION
This study sought to determine the incidence of three previously identified factor XI gene mutations in a large group of factor XI-deficient patients and to investigate whether the factor XI genotype correlated with the clinical severity of the bleeding diathesis. Three main conclusions can be drawn from the data presented here.
First, a significant proportion (2.5%) of the mutant alleles causing factor XI deficiency in our patient sample remain to be identified. It is interesting that none of our patients possessed the type I (splice donor) mutation described by Asakai et aI.l5 These investigators identified the mutation in only one of 12 alleles studied. One interpretation of these observations is that whereas the type I1 (premature termination) and type 111 (amino acid substitution) factor XI gene mutations clearly predominate in Jewish populations, a number of individually uncommon mutations (eg, type I) account for the remaining 25% of disease alleles found mainly in non-Jews. We are currently sequencing the factor XI genes of patients with undefined mutations to address this hypothesis. It is also possible that one or more of these undefined mutations may be non-allelic, ie, they occur at other loci whose gene products are required for normal expression of the factor XI gene.
Second, as mentioned above, the frequencies of the two common factor XI gene mutations differ significantly between Jewish and non-Jewish patients. Indeed, the majority (84%) of the disease alleles in non-Jews remain undefined. These differences are probably not surprising in view of the early finding that non-Jewish homozygotes and heterozygotes possessed lower plasma factor XI levels than their Jewish counterparts.'' The high incidence of factor XI deficiency among Ashkenazi Jews was initially attributed to a founder effect. The results of our study are in part consistent with this hypothesis in that two distinct mutations account for 88% of all factor XI gene defects in this ethnic group. Our observation that these same mutations are rare in non-Jewish patients is also consistent with this interpretation, especially if several undefined mutations exist, rather than just a single mutation. The high frequency of factor XI deficiency among Ashkenazi Jews due to a minimum of four distinct mutations is nevertheless intriguing. Some selective advantage may well have accrued to heterozygous carriers of the mutant alleles to account for their high frequency in this ethnic group."
Third, the comparative analysis of phenotype and genotype presented here suggests that patients with a II/III genotype are significantly more likely to experience moderate bleeding than patients with other genotypes. Of the patients with a II/III genotype, approximately SO% had a moderate bleeding tendency and 50% had a mild clinical picture. Indeed, six of seven of the patients who had a moderate bleeding tendency possessed this genotype. This result indicates that a knowledge of a factor XI-deficient patient's genotype may be of some use in predicting the Eleven patient pedigrees. The plasma factor XI:C level is recorded in the patients' box or circle. Underneath each patient, in parentheses, is given their genotype followed, after a comma, by their bleeding phenotype according t o the key given below. For example, (I1 111. 2) indicates a double heterozygote 11/111 genotype with a moderate bleeding diathesis. If a single mutation is recorded, the patient is a heterozygote. All kindreds are Jewish except for groups 9 and 11, which are non-Jewish. U, undefined mutation; 0, none/trivial bleeding; 1, mild bleeding tendency; 2, moderate bleeding tendency; -, data not available.
For personal use only. on October 30, 2017. by guest www.bloodjournal.org From likely outcome to an elective hemostatic challenge. Our data also show that there is an association between plasma factor XI:C levels and a patient's genotype. In other words, the mean factor XI:C levels associated with individual homozygous and compound heterozygous genotypes differ significantly. We speculate that, for the three genotypes containing only defined mutations, the associated factor XI:C levels may be rationalized as follows. Dimers of a completely truncated factor XI molecule lack the catalytic site and are probably also unstable. This inactivity and instability would be reflected in the very low factor XI levels associated with the 11/11 genotype. Conversely, the missense mutation associated with the I11 mutation would not be expected to alter the stability of the protein because a bulky hydrophobic residue is merely replaced by a smaller aliphatic amino acid. In this case, stable dimers of a III/III protein should be produced that have limited activity. Although we do not as yet have confirmatory factor X1:Ag data, the observed higher factor XI:C level of type I11 homozygotes (11 U/dL) compared with that of type I1 homozygotes (0.6 U/dL) is consistent with this interpretation. Coexpression of type I1 and type I11 polypeptides in the same cell will result in the formation of 11/11 and III/III homodimers plus heterodimers of II/III protein. The amount of III/III protein secreted from heterozygous II/III liver cells would, therefore, be approximately 25% of that secreted by a homozygous III/III liver cell. This hypothesis fits with the observed mean factor XI:C level associated with the II/III genotype (2.9 U/dL). The question then arises as to whether II/III dimers are formed and secreted in II/III heterozygotes. The formation of such dimers may serve to stabilize the type I1 truncated chain resulting in a molecule that, despite lacking significant coagulant activity, can still bind HMWK because both binding sites for this molecule (Phe 56-Ser 86) would be present. The greater phenotypic severity associated with the II/III genotype might, therefore, be explained by a combination of HMWK depletion, due to sequestration by inactive II/III molecules, and a reduced production (relative to the III/III genotype) of the weakly active III/III homodimer.
APPENDIX
Eleven patient pedigrees are listed (Fig 4) .
